Skip to main content
. 2019 Jul 15;104(10):4730–4742. doi: 10.1210/jc.2019-00775

Figure 3.

Figure 3.

(a) Sex, (b) age at treatment start, (c) height SDS (HSDS), (d) IGF-I SDS, and (e) dose of GH at treatment start by diagnostic group in NordiNet IOS and ANSWER. All data are for patients included in the EAS; data are mean (SD). Approved doses (mg/kg/d) are shown below each diagnostic group. aISS is not an approved indication in Europe. bApproved in Switzerland and Japan. cApproved in Switzerland.